Abstract:Toxicogenomics (TGx) can be considered as a maturing discipline that aims to delineate the complex molecular response to environmental stress and chemicals as well as to drug treatment. Different types of TGx studies have different goals: (1) mechanistic toxicology TGx aims at revealing the molecular basis of toxicity mechanisms; (2) comparative toxicology TGx compares gene expression change patterns among many chemicals to identify their sharing modes of action; and (3) predictive toxicology TGx develops and validates a predictive signature or biomarker for a specific toxicity. Regardless of study type, the TGx data are both prodigious and highly complex, making biologically sound conclusions drawn from proper interpretation strategies a difficult overtaking. This chapter covers a broad range of topics related to TGx study data interpretation. Strategies such as pathway and functional analysis, chromosome mapping, and integration with data from other omics platforms are discussed. Phenotypic anchoring, the process of causality associating the gene expression alteration with phenotypic outcome, is also discussed. Integrating genomics data with proteomics and/or metabolomics data, the so-called systems toxicology approach, is another powerful interpretive approach. Public and private databases enabling interpretive context and software to integrate and analyze data are also summarized. For all the different interpretation techniques provided throughout the chapter, examples of studies and available tools are also provided. Most importantly, the issues and challenges associated with these topics are emphasized so that the readers can gain an overall perspective of preferred approaches for using the existing technology. The ways and means of interpreting TGx data is evolving rapidly. The authors ardently expect that the snapshot of current methods outlined here will soon be refined, or replaced with new innovations, paving the way for a paradigm shift in the toxicological sciences.

Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective

Interpretation of Toxicogenomics Data

Research progress in drug toxicology based on systems biology

Application of genomics in preclinical drug safety evaluation.

Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology

Review of Current and “omics” Methods for Assessing the Toxicity (genotoxicity, Teratogenicity and Nephrotoxicity) of Herbal Medicines and Mushrooms

Toxicogenomics and drug discovery: will new technologies help us produce better drugs?

Toxicogenomics: A 2020 Vision.

Progress and promises in toxicogenomics in aquatic toxicology: Is technical innovation driving scientific innovation?

Progress in toxicogenomics to protect human health

Toxicogenomics Approaches to Address Toxicity and Carcinogenicity in the Liver

In Pursuit of Effective Toxicogenomics

Genomic and Proteomic Approaches for Predicting Toxicity and Adverse Drug Reactions.

Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends

Quantitative systems toxicology modeling in pharmaceutical research and development: An industry‐wide survey and selected case study examples

Metabonomics: its potential as a tool in toxicology for safety assessment and data integration

Using human genetics to improve safety assessment of therapeutics

Prospects for Applying Synthetic Biology to Toxicology: Future Opportunities and Current Limitations for the Repurposing of Cytochrome P450 Systems

The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development

Setting the stage for next-generation risk assessment with non-animal approaches: the EU-ToxRisk project experience